Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial

By sjmartinez • July 18, 2023

Belperio J, Nguyen T, Lombardi DA, Bogus M, Moskalenko V, Singh D, Haumann B, Bourdet DL, Kaufman E, Pfeifer ND, Thompson CG, Woo J, Moran EJ, Saggar R. Efficacy and safety of an inhaled pan-Janus kinase inhibitor, nezulcitinib, in hospitalised patients with COVID-19: results from a phase 2 clinical trial. BMJ Open Respir Res. 2023 Jul;10(1):e001627. doi: 10.1136/bmjresp-2023-001627. PMID: 37460276.

Tags: covid-19, Nebuliser therapy, Publications, Pulmonary, Critical Care & Sleep Medicine

Genetic Research within Indigenous Communities: Engagement Opportunities and Pathways Forward

Barton KS, Porter KM, Mai T, Claw KG, Hiratsuka VY, Carroll SR, Burke W, Garrison NA. Genetic Research within Indigenous Communities: Engagement Opportunities and Pathways[...]

Maintained renin-angiotensin-aldosterone system inhibitor therapy with sodium zirconium cyclosilicate following a hyperkalaemia episode: a multicountry cohort study

Rastogi A, Pollack CV Jr, Sánchez Lázaro IJ, Lesén E, Arnold M, Franzén S, Allum A, Hernández I, Murohara T, Kanda E. Maintained renin-angiotensin-aldosterone system[...]

A Tale of Two Islands – Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights

Haake DA. A Tale of Two Islands - Leptospirosis in Strikingly Different Ecological Settings Reveals Pathogenomic Insights. Am J Trop Med Hyg. 2024 May 2:tpmd240254.[...]